Daniel Quirk

549 total citations
20 papers, 390 citations indexed

About

Daniel Quirk is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Daniel Quirk has authored 20 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 13 papers in Epidemiology and 6 papers in Surgery. Recurrent topics in Daniel Quirk's work include Inflammatory Bowel Disease (18 papers), Microscopic Colitis (13 papers) and Biosimilars and Bioanalytical Methods (4 papers). Daniel Quirk is often cited by papers focused on Inflammatory Bowel Disease (18 papers), Microscopic Colitis (13 papers) and Biosimilars and Bioanalytical Methods (4 papers). Daniel Quirk collaborates with scholars based in United States, Italy and Spain. Daniel Quirk's co-authors include Chinyu Su, Chudy I. Nduaka, Gary S. Friedman, Nervin Lawendy, Haiying Zhang, Walter Reinisch, Deborah Woodworth, Peter Higgins, Adam S. Cheifetz and Bruce E. Sands and has published in prestigious journals such as Gastroenterology, PLoS ONE and The American Journal of Gastroenterology.

In The Last Decade

Daniel Quirk

20 papers receiving 385 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Quirk United States	11	315	229	109	66	57	20	390
Eric Maller United States	6	251 0.8×	152 0.7×	124 1.1×	85 1.3×	65 1.1×	12	437
Timothy E. Ritter United States	11	279 0.9×	215 0.9×	110 1.0×	45 0.7×	38 0.7×	38	442
Juan S. Lasa Argentina	7	167 0.5×	122 0.5×	82 0.8×	90 1.4×	47 0.8×	19	355
Omid Shaye United States	9	177 0.6×	147 0.6×	168 1.5×	39 0.6×	80 1.4×	11	428
Maria Weidinger Germany	9	272 0.9×	162 0.7×	80 0.7×	66 1.0×	27 0.5×	15	408
B G Feagan Canada	7	369 1.2×	262 1.1×	90 0.8×	58 0.9×	40 0.7×	28	512
Andre M. Van Gossum Belgium	5	297 0.9×	234 1.0×	106 1.0×	29 0.4×	33 0.6×	12	379
B E Sands United States	10	274 0.9×	200 0.9×	90 0.8×	29 0.4×	33 0.6×	77	334
Javaid Subhani United Kingdom	6	305 1.0×	211 0.9×	101 0.9×	19 0.3×	44 0.8×	12	466
Ivan Ferkolj Slovenia	11	276 0.9×	193 0.8×	120 1.1×	23 0.3×	27 0.5×	23	416

Countries citing papers authored by Daniel Quirk

Since Specialization

Citations

This map shows the geographic impact of Daniel Quirk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Quirk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Quirk more than expected).

Fields of papers citing papers by Daniel Quirk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Quirk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Quirk. The network helps show where Daniel Quirk may publish in the future.

Co-authorship network of co-authors of Daniel Quirk

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Quirk. A scholar is included among the top collaborators of Daniel Quirk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Quirk. Daniel Quirk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sandborn, William J., Laurent Peyrin‐Biroulet, Daniel Quirk, et al.. (2020). Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 20(8). 1821–1830.e3. 54 indexed citations

Armuzzi, Alessandro, M. Tarallo, James Lucas, et al.. (2020). Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS ONE. 15(1). e0227914–e0227914. 33 indexed citations

Colombel, Jean‐Frédéric, Mark T. Osterman, Andrew Thorpe, et al.. (2020). Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 20(1). 116–125.e5. 31 indexed citations

Sandborn, William J., Julián Panés, Bruce E. Sands, et al.. (2020). P598 Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme: An update as of May 2019. Journal of Crohn s and Colitis. 14(Supplement_1). S498–S500. 2 indexed citations

Lichtenstein, Gary R., Gerhard Rogler, Matthew A. Ciorba, et al.. (2020). Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program. Inflammatory Bowel Diseases. 27(6). 816–825. 20 indexed citations

Sands, Bruce E., Jean‐Frédéric Colombel, Christina Ha, et al.. (2020). Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management. Inflammatory Bowel Diseases. 27(6). 797–808. 27 indexed citations

Lee, Scott D., Raina Shivashankar, Daniel Quirk, et al.. (2020). Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. Journal of Clinical Gastroenterology. 55(3). 195–206. 14 indexed citations

Sands, Bruce E., Adam S. Cheifetz, Chudy I. Nduaka, et al.. (2019). The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. Journal of Crohn s and Colitis. 13(9). 1217–1226. 10 indexed citations

Rubin, David T., Daniel Quirk, Chudy I. Nduaka, et al.. (2019). DOP43 Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders. Journal of Crohn s and Colitis. 13(Supplement_1). S050–S052. 4 indexed citations

10.

Lichtenstein, Gary R., Matthew A. Ciorba, Gerhard Rogler, et al.. (2019). 705 Tofacitinib for the Treatment of Ulcerative Colitis: An Update on the Analysis of Malignancy Rates From the UC Clinical Program. The American Journal of Gastroenterology. 114(1). S414–S415. 1 indexed citations

11.

Smith, Timothy M., et al.. (2019). P025 Real-world effectiveness of biologic therapies among patients with moderate-to-severe ulcerative colitis in the United States. The American Journal of Gastroenterology. 114(1). S7–S7. 1 indexed citations

12.

DiBonaventura, Marco, et al.. (2019). An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. Journal of Medical Economics. 22(9). 859–868. 15 indexed citations

13.

Hanauer, Stephen B., David T. Rubin, Paolo Gionchetti, et al.. (2019). P712 Tofacitinib efficacy in patients with moderate to severe ulcerative colitis: Subgroup analyses of OCTAVE Induction 1 and 2 and OCTAVE Sustain by 5-aminosalicylates use. Journal of Crohn s and Colitis. 13(Supplement_1). S477–S477. 3 indexed citations

14.

Lichtenstein, Gary R., Benjamin L. Cohen, Leonardo Salese, et al.. (2019). 706 Impact of Baseline Corticosteroid Therapy on Tofacitinib Induction Efficacy and Infection Risk in Patients With Ulcerative Colitis: Data From Global Clinical Trials. The American Journal of Gastroenterology. 114(1). S415–S415. 4 indexed citations

15.

Smith, Timothy M., et al.. (2019). P024 Treatment patterns of biologic therapies used to treat ulcerative colitis: A retrospective database analysis in the United States. The American Journal of Gastroenterology. 114(1). S7–S7. 2 indexed citations

16.

Hanauer, Stephen B., Remo Panaccione, Silvio Danese, et al.. (2018). Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 17(1). 139–147. 132 indexed citations

17.

Sands, B E, Pam R. Taub, Brian G. Feagan, et al.. (2018). OP033 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme. Journal of Crohn s and Colitis. 12(supplement_1). S023–S023. 3 indexed citations

18.

Sands, Bruce E., Pam R. Taub, Brian G. Feagan, et al.. (2018). Sa1750 - The Effect of Tofacitinib on Serum Lipids and Cardiovascular Safety in Patients with Ulcerative Colitis - Results from the Tofacitinib Ulcerative Colitis Clinical Program. Gastroenterology. 154(6). S–380. 1 indexed citations

19.

Dubinsky, Marla C., Laurent Peyrin‐Biroulet, Gil Melmed, et al.. (2017). Efficacy of Tofacitinib in Patients With Ulcerative Colitis by Prior Tumor Necrosis Factor Inhibitor Treatment Status: Results From OCTAVE Induction and Maintenance Studies. The American Journal of Gastroenterology. 112. S354–S354. 11 indexed citations

20.

Stern, Judy E., et al.. (1992). Secretory immune system of the male reproductive tract: effects of dihydrotestosterone and estradiol on IgA and secretory component levels. Journal of Reproductive Immunology. 22(1). 73–85. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact